Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1400 entries
Sorted by: Best Match Show Resources per page
Imatinib treatment reduces brain injury in a murine model of traumatic brain injury.

Frontiers in cellular neuroscience

Su EJ, Fredriksson L, Kanzawa M, Moore S, Folestad E, Stevenson TK, Nilsson I, Sashindranath M, Schielke GP, Warnock M, Ragsdale M, Mann K, Lawrence AL, Medcalf RL, Eriksson U, Murphy GG, Lawrence DA.
PMID: 26500491
Front Cell Neurosci. 2015 Oct 07;9:385. doi: 10.3389/fncel.2015.00385. eCollection 2015.

Current therapies for Traumatic brain injury (TBI) focus on stabilizing individuals and on preventing further damage from the secondary consequences of TBI. A major complication of TBI is cerebral edema, which can be caused by the loss of blood...

Cite
Su EJ, Fredriksson L, Kanzawa M, et al. Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Front Cell Neurosci. 2015;9:385doi: 10.3389/fncel.2015.00385.
Su, E. J., Fredriksson, L., Kanzawa, M., Moore, S., Folestad, E., Stevenson, T. K., Nilsson, I., Sashindranath, M., Schielke, G. P., Warnock, M., Ragsdale, M., Mann, K., Lawrence, A. L., Medcalf, R. L., Eriksson, U., Murphy, G. G., & Lawrence, D. A. (2015). Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Frontiers in cellular neuroscience, 9385. https://doi.org/10.3389/fncel.2015.00385
Su, Enming J, et al. "Imatinib treatment reduces brain injury in a murine model of traumatic brain injury." Frontiers in cellular neuroscience vol. 9 (2015): 385. doi: https://doi.org/10.3389/fncel.2015.00385
Su EJ, Fredriksson L, Kanzawa M, Moore S, Folestad E, Stevenson TK, Nilsson I, Sashindranath M, Schielke GP, Warnock M, Ragsdale M, Mann K, Lawrence AL, Medcalf RL, Eriksson U, Murphy GG, Lawrence DA. Imatinib treatment reduces brain injury in a murine model of traumatic brain injury. Front Cell Neurosci. 2015 Oct 07;9:385. doi: 10.3389/fncel.2015.00385. eCollection 2015. PMID: 26500491; PMCID: PMC4596067.
Copy Download .nbib Format: NLM
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.

Oncotarget

Ruffini F, Levati L, Graziani G, Caporali S, Atzori MG, D'Atri S, Lacal PM.
PMID: 28977999
Oncotarget. 2017 Jun 27;8(40):66833-66848. doi: 10.18632/oncotarget.18706. eCollection 2017 Sep 15.

Despite recent progress in advanced melanoma therapy, identification of signalling pathways involved in melanoma switch from proliferative to invasive states is still crucial to uncover new therapeutic targets for improving the outcome of metastatic disease. Neuropilin-1 (NRP-1), a co-receptor...

Cite
Ruffini F, Levati L, Graziani G, et al. Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget. 2017;8(40):66833-66848doi: 10.18632/oncotarget.18706.
Ruffini, F., Levati, L., Graziani, G., Caporali, S., Atzori, M. G., D'Atri, S., & Lacal, P. M. (2017). Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget, 8(40), 66833-66848. https://doi.org/10.18632/oncotarget.18706
Ruffini, Federica, et al. "Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1." Oncotarget vol. 8,40 (2017): 66833-66848. doi: https://doi.org/10.18632/oncotarget.18706
Ruffini F, Levati L, Graziani G, Caporali S, Atzori MG, D'Atri S, Lacal PM. Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget. 2017 Jun 27;8(40):66833-66848. doi: 10.18632/oncotarget.18706. eCollection 2017 Sep 15. PMID: 28977999; PMCID: PMC5620139.
Copy Download .nbib Format: NLM
Quantifying Aptamer-Protein Binding via Thermofluorimetric Analysis.

Analytical methods : advancing methods and applications

Hu J, Kim J, Easley CJ.
PMID: 26366207
Anal Methods. 2015 Sep 07;7(17):7358-7362. doi: 10.1039/c5ay00837a.

Effective aptamer-based protein assays require coupling to a quantitative reporter of aptamer-protein binding. Typically, this involves a direct optical or electrochemical readout of DNA hybridization or an amplification step coupled to the readout. However, method development is often hampered...

Cite
Hu J, Kim J, Easley CJ. Quantifying Aptamer-Protein Binding via Thermofluorimetric Analysis. Anal Methods. 2015;7(17):7358-7362doi: 10.1039/c5ay00837a.
Hu, J., Kim, J., & Easley, C. J. (2015). Quantifying Aptamer-Protein Binding via Thermofluorimetric Analysis. Analytical methods : advancing methods and applications, 7(17), 7358-7362. https://doi.org/10.1039/c5ay00837a
Hu, Juan, et al. "Quantifying Aptamer-Protein Binding via Thermofluorimetric Analysis." Analytical methods : advancing methods and applications vol. 7,17 (2015): 7358-7362. doi: https://doi.org/10.1039/c5ay00837a
Hu J, Kim J, Easley CJ. Quantifying Aptamer-Protein Binding via Thermofluorimetric Analysis. Anal Methods. 2015 Sep 07;7(17):7358-7362. doi: 10.1039/c5ay00837a. PMID: 26366207; PMCID: PMC4562029.
Copy Download .nbib Format: NLM
Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis.

Kidney international supplements

Ostendorf T, Boor P, van Roeyen CR, Floege J.
PMID: 26312152
Kidney Int Suppl (2011). 2014 Nov;4(1):65-69. doi: 10.1038/kisup.2014.12.

Renal fibrosis is the hallmark of chronic kidney disease progression and is characterized by an exaggerated wound-healing process with the production of renal scar tissue. It comprises both the glomerular and the tubulointerstitial compartments. Among the factors that contribute...

Cite
Ostendorf T, Boor P, van Roeyen CR, et al. Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney Int Suppl (2011). 2014;4(1):65-69doi: 10.1038/kisup.2014.12.
Ostendorf, T., Boor, P., van Roeyen, C. R., & Floege, J. (2014). Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney international supplements, 4(1), 65-69. https://doi.org/10.1038/kisup.2014.12
Ostendorf, Tammo, et al. "Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis." Kidney international supplements vol. 4,1 (2014): 65-69. doi: https://doi.org/10.1038/kisup.2014.12
Ostendorf T, Boor P, van Roeyen CR, Floege J. Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney Int Suppl (2011). 2014 Nov;4(1):65-69. doi: 10.1038/kisup.2014.12. PMID: 26312152; PMCID: PMC4536969.
Copy Download .nbib Format: NLM
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Core evidence

Inomata M, Nishioka Y, Azuma A.
PMID: 26346347
Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015.

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role...

Cite
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015;10:89-98doi: 10.2147/CE.S82905.
Inomata, M., Nishioka, Y., & Azuma, A. (2015). Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core evidence, 1089-98. https://doi.org/10.2147/CE.S82905
Inomata, Minoru, et al. "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis." Core evidence vol. 10 (2015): 89-98. doi: https://doi.org/10.2147/CE.S82905
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015. PMID: 26346347; PMCID: PMC4555978.
Copy Download .nbib Format: NLM
Quality Assessment of Platelet-Rich Fibrin-Like Matrix Prepared from Whole Blood Samples after Extended Storage.

Biomedicines

Kawabata H, Isobe K, Watanabe T, Okudera T, Nakamura M, Suzuki M, Ryu J, Kitamura Y, Okudera H, Okuda K, Nakata K, Kawase T.
PMID: 28926988
Biomedicines. 2017 Sep 18;5(3). doi: 10.3390/biomedicines5030057.

The platelet-rich fibrin-like matrix (PRFM) is usually prepared onsite and immediately used for regenerative therapy. Nonetheless, to meet the clinical necessity of preserving the PRFM without quality deterioration, we developed a method for preparation of PRFMs from short-term-stored whole...

Cite
Kawabata H, Isobe K, Watanabe T, et al. Quality Assessment of Platelet-Rich Fibrin-Like Matrix Prepared from Whole Blood Samples after Extended Storage. Biomedicines. 2017;5(3)doi: 10.3390/biomedicines5030057.
Kawabata, H., Isobe, K., Watanabe, T., Okudera, T., Nakamura, M., Suzuki, M., Ryu, J., Kitamura, Y., Okudera, H., Okuda, K., Nakata, K., & Kawase, T. (2017). Quality Assessment of Platelet-Rich Fibrin-Like Matrix Prepared from Whole Blood Samples after Extended Storage. Biomedicines, 5(3), . https://doi.org/10.3390/biomedicines5030057
Kawabata, Hideo, et al. "Quality Assessment of Platelet-Rich Fibrin-Like Matrix Prepared from Whole Blood Samples after Extended Storage." Biomedicines vol. 5,3 (2017). doi: https://doi.org/10.3390/biomedicines5030057
Kawabata H, Isobe K, Watanabe T, Okudera T, Nakamura M, Suzuki M, Ryu J, Kitamura Y, Okudera H, Okuda K, Nakata K, Kawase T. Quality Assessment of Platelet-Rich Fibrin-Like Matrix Prepared from Whole Blood Samples after Extended Storage. Biomedicines. 2017 Sep 18;5(3). doi: 10.3390/biomedicines5030057. PMID: 28926988; PMCID: PMC5618315.
Copy Download .nbib Format: NLM
Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells.

OncoTargets and therapy

Li Y, Li Y, Liu Q, Wang A.
PMID: 25999739
Onco Targets Ther. 2015 May 14;8:1043-51. doi: 10.2147/OTT.S70691. eCollection 2015.

Melanoma is the deadliest form of skin cancer, and BRAFV600E is a driver mutation that promotes melanoma growth and survival. PLX4032 is the first effective compound in clinical use for the treatment of patients with mutant BRAFV600. However, resistance...

Cite
Li Y, Li Y, Liu Q, et al. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. Onco Targets Ther. 2015;8:1043-51doi: 10.2147/OTT.S70691.
Li, Y., Li, Y., Liu, Q., & Wang, A. (2015). Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. OncoTargets and therapy, 81043-51. https://doi.org/10.2147/OTT.S70691
Li, Yanling, et al. "Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells." OncoTargets and therapy vol. 8 (2015): 1043-51. doi: https://doi.org/10.2147/OTT.S70691
Li Y, Li Y, Liu Q, Wang A. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. Onco Targets Ther. 2015 May 14;8:1043-51. doi: 10.2147/OTT.S70691. eCollection 2015. PMID: 25999739; PMCID: PMC4437616.
Copy Download .nbib Format: NLM
Inflammatory fibroid polyp: a rare benign tumor of the alimentary tract in children presenting as intussusception-case report and review of literature.

European journal of pediatric surgery reports

Siminas S, Qasem E, Shukla R, Turnock R.
PMID: 25755961
European J Pediatr Surg Rep. 2014 Jun;2(1):16-9. doi: 10.1055/s-0033-1354746. Epub 2013 Sep 09.

Inflammatory fibroid polyp (IFP) represents a rare cause of gastrointestinal polypoid disease in childhood. Τhe lesion has been described by various names beyond the currently accepted term, including "Vanek's tumour," eosinophilic or submucosal granuloma, gastric fibroma with eosinophilic infiltration,...

Cite
Siminas S, Qasem E, Shukla R, et al. Inflammatory fibroid polyp: a rare benign tumor of the alimentary tract in children presenting as intussusception-case report and review of literature. European J Pediatr Surg Rep. 2013;2(1):16-9doi: 10.1055/s-0033-1354746.
Siminas, S., Qasem, E., Shukla, R., & Turnock, R. (2014). Inflammatory fibroid polyp: a rare benign tumor of the alimentary tract in children presenting as intussusception-case report and review of literature. European journal of pediatric surgery reports, 2(1), 16-9. https://doi.org/10.1055/s-0033-1354746
Siminas, Sotirios, et al. "Inflammatory fibroid polyp: a rare benign tumor of the alimentary tract in children presenting as intussusception-case report and review of literature." European journal of pediatric surgery reports vol. 2,1 (2014): 16-9. doi: https://doi.org/10.1055/s-0033-1354746
Siminas S, Qasem E, Shukla R, Turnock R. Inflammatory fibroid polyp: a rare benign tumor of the alimentary tract in children presenting as intussusception-case report and review of literature. European J Pediatr Surg Rep. 2014 Jun;2(1):16-9. doi: 10.1055/s-0033-1354746. Epub 2013 Sep 09. PMID: 25755961; PMCID: PMC4336055.
Copy Download .nbib Format: NLM
Gastrointestinal stromal tumor with a .

Oncology letters

Zhou J, Xu J, Jiang G, Ma Y, Qi J, Li W, Zhang D.
PMID: 28356974
Oncol Lett. 2017 Feb;13(2):887-892. doi: 10.3892/ol.2016.5486. Epub 2016 Dec 12.

Gastric plexiform fibromyxoma (PF) is a rare mesenchymal tumor with a histologically distinctive multinodular pattern, dissimilar to conventional gastrointestinal stromal tumor (GIST). The current study presents one case of gastric PF, and one case of GIST with a platelet-derived...

Cite
Zhou J, Xu J, Jiang G, et al. Gastrointestinal stromal tumor with a . Oncol Lett. 2016;13(2):887-892doi: 10.3892/ol.2016.5486.
Zhou, J., Xu, J., Jiang, G., Ma, Y., Qi, J., Li, W., & Zhang, D. (2017). Gastrointestinal stromal tumor with a . Oncology letters, 13(2), 887-892. https://doi.org/10.3892/ol.2016.5486
Zhou, Jun, et al. "Gastrointestinal stromal tumor with a ." Oncology letters vol. 13,2 (2017): 887-892. doi: https://doi.org/10.3892/ol.2016.5486
Zhou J, Xu J, Jiang G, Ma Y, Qi J, Li W, Zhang D. Gastrointestinal stromal tumor with a . Oncol Lett. 2017 Feb;13(2):887-892. doi: 10.3892/ol.2016.5486. Epub 2016 Dec 12. PMID: 28356974; PMCID: PMC5351284.
Copy Download .nbib Format: NLM
Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy.

Oncology letters

Higuchi A, Oshima T, Yoshihara K, Sakamaki K, Aoyama T, Suganuma N, Yamamoto N, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Kunisaki C, Imada T, Masuda M.
PMID: 28356977
Oncol Lett. 2017 Feb;13(2):905-911. doi: 10.3892/ol.2016.5494. Epub 2016 Dec 14.

Overall survival remains unsatisfactory in stage II/III gastric cancer, even after curative surgery and adjuvant chemotherapy. Platelet-derived growth factor receptor-β (

Cite
Higuchi A, Oshima T, Yoshihara K, et al. Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. Oncol Lett. 2016;13(2):905-911doi: 10.3892/ol.2016.5494.
Higuchi, A., Oshima, T., Yoshihara, K., Sakamaki, K., Aoyama, T., Suganuma, N., Yamamoto, N., Sato, T., Cho, H., Shiozawa, M., Yoshikawa, T., Rino, Y., Kunisaki, C., Imada, T., & Masuda, M. (2017). Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. Oncology letters, 13(2), 905-911. https://doi.org/10.3892/ol.2016.5494
Higuchi, Akio, et al. "Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy." Oncology letters vol. 13,2 (2017): 905-911. doi: https://doi.org/10.3892/ol.2016.5494
Higuchi A, Oshima T, Yoshihara K, Sakamaki K, Aoyama T, Suganuma N, Yamamoto N, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Kunisaki C, Imada T, Masuda M. Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. Oncol Lett. 2017 Feb;13(2):905-911. doi: 10.3892/ol.2016.5494. Epub 2016 Dec 14. PMID: 28356977; PMCID: PMC5351282.
Copy Download .nbib Format: NLM
Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors.

Endocrinology, diabetes & metabolism case reports

Yavropoulou MP, Gerothanasi N, Frydas A, Triantafyllou E, Poulios C, Hytiroglou P, Apostolou P, Papasotiriou I, Tournis S, Kesisoglou I, Yovos JG.
PMID: 26155363
Endocrinol Diabetes Metab Case Rep. 2015;2015:150025. doi: 10.1530/EDM-15-0025. Epub 2015 May 27.

UNLABELLED: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused primarily by benign mesenchymal tumors. These tumors typically follow a benign clinical course and local recurrence occurs in

Cite
Yavropoulou MP, Gerothanasi N, Frydas A, et al. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep. 2015;2015:150025doi: 10.1530/EDM-15-0025.
Yavropoulou, M. P., Gerothanasi, N., Frydas, A., Triantafyllou, E., Poulios, C., Hytiroglou, P., Apostolou, P., Papasotiriou, I., Tournis, S., Kesisoglou, I., & Yovos, J. G. (2015). Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinology, diabetes & metabolism case reports, 2015150025. https://doi.org/10.1530/EDM-15-0025
Yavropoulou, Maria P, et al. "Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors." Endocrinology, diabetes & metabolism case reports vol. 2015 (2015): 150025. doi: https://doi.org/10.1530/EDM-15-0025
Yavropoulou MP, Gerothanasi N, Frydas A, Triantafyllou E, Poulios C, Hytiroglou P, Apostolou P, Papasotiriou I, Tournis S, Kesisoglou I, Yovos JG. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep. 2015;2015:150025. doi: 10.1530/EDM-15-0025. Epub 2015 May 27. PMID: 26155363; PMCID: PMC4489167.
Copy Download .nbib Format: NLM
Pleural mesothelial cells in pleural and lung diseases.

Journal of thoracic disease

Batra H, Antony VB.
PMID: 26150910
J Thorac Dis. 2015 Jun;7(6):964-80. doi: 10.3978/j.issn.2072-1439.2015.02.19.

During development, the mesoderm maintains a complex relationship with the developing endoderm giving rise to the mature lung. Pleural mesothelial cells (PMCs) derived from the mesoderm play a key role during the development of the lung. The pleural mesothelium...

Cite
Batra H, Antony VB. Pleural mesothelial cells in pleural and lung diseases. J Thorac Dis. 2015;7(6):964-80doi: 10.3978/j.issn.2072-1439.2015.02.19.
Batra, H., & Antony, V. B. (2015). Pleural mesothelial cells in pleural and lung diseases. Journal of thoracic disease, 7(6), 964-80. https://doi.org/10.3978/j.issn.2072-1439.2015.02.19
Batra, Hitesh, and Antony, Veena B. "Pleural mesothelial cells in pleural and lung diseases." Journal of thoracic disease vol. 7,6 (2015): 964-80. doi: https://doi.org/10.3978/j.issn.2072-1439.2015.02.19
Batra H, Antony VB. Pleural mesothelial cells in pleural and lung diseases. J Thorac Dis. 2015 Jun;7(6):964-80. doi: 10.3978/j.issn.2072-1439.2015.02.19. PMID: 26150910; PMCID: PMC4466423.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1400 entries